<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Can ALNY&#x27;s Key Partnerships With Pharma Giants Drive Long-Term Growth? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Can ALNY&#x27;s Key Partnerships With Pharma Giants Drive Long-Term Growth?</h2>
    <div class="badge">2025-09-08T14:15:00+00:00</div>
    <ul>
      <li>The drug generated $801.9 million in global sales in the first half of 2025, representing a staggering 89% year-over-year growth, driven by patient demand.</li>
<li>Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo, and Amvuttra — which together generated $1.14 billion in net product revenues, representing a 47% year-over-year increase i</li>
<li>Building on positive phase II KARDIA data, Alnylam and Roche plan to launch the global phase III ZENITH CV outcomes study by late 2025, enrolling about 11,000 high-risk hypertension patients.</li>
<li>The agreement regarding cemdisiran underwent a modification last year.</li>
<li>Alnylam, in collaboration with Roche, is developing investigational RNAi therapy zilebesiran in a mid-stage study (KARDIA-3) to treat hypertension.</li>
<li>The study will test whether twice-yearly 300 mg doses of zilebesiran can reduce the risk of major adverse cardiovascular events compared to placebo.</li>
<li>Recently, the companies reported encouraging Cohort A results, where a single 300 mg dose of zilebesiran achieved clinically meaningful and sustained reductions in office and ambulatory systolic blood pressure, as well a</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Can%20ALNY%27s%20Key%20Partnerships%20With%20Pharma%20Giants%20Drive%20Long-Term%20Growth%3F%0A%E2%80%A2%20The%20drug%20generated%20%24801.9%20million%20in%20global%20sales%20in%20the%20first%20half%20of%202025%2C%20representing%20a%20staggering%2089%25%20year-over-year%20growth%2C%20driven%20by%20patient%20demand.%0A%E2%80%A2%20Alnylam%20Pharmaceuticals%20ALNY%20currently%20markets%20four%20approved%20drugs%20%E2%80%94%20Onpattro%2C%20Givlaari%2C%20Oxlumo%2C%20and%20Amvuttra%20%E2%80%94%20which%20together%20generated%20%241.14%20billion%20in%20net%20product%20revenues%2C%20representing%20a%2047%25%20year-over-year%20increase%20i%0A%E2%80%A2%20Building%20on%20positive%20phase%20II%20KARDIA%20data%2C%20Alnylam%20and%20Roche%20plan%20to%20launch%20the%20global%20phase%20III%20ZENITH%20CV%20outcomes%20study%20by%20late%202025%2C%20enrolling%20about%2011%2C000%20high-risk%20hypertension%20patients.%0A%E2%80%A2%20The%20agreement%20regarding%20cemdisiran%20underwent%20a%20modification%20last%20year.%0A%E2%80%A2%20Alnylam%2C%20in%20collaboration%20with%20Roche%2C%20is%20developing%20investigational%20RNAi%20therapy%20zilebesiran%20in%20a%20mid-stage%20study%20%28KARDIA-3%29%20to%20treat%20hypertension.%0A%E2%80%A2%20The%20study%20will%20test%20whether%20twice-yearly%20300%20mg%20doses%20of%20zilebesiran%20can%20reduce%20the%20risk%20of%20major%20adverse%20cardiovascular%20events%20compared%20to%20placebo.%0A%E2%80%A2%20Recently%2C%20the%20companies%20reported%20encouraging%20Cohort%20A%20results%2C%20where%20a%20single%20300%20mg%20dose%20of%20zilebesiran%20achieved%20clinically%20meaningful%20and%20sustained%20reductions%20in%20office%20and%20ambulatory%20systolic%20blood%20pressure%2C%20as%20well%20a&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fcan-alny-s-key-partnerships-with-pharma-giants-drive-long-term-growth%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/alnys-key-partnerships-pharma-giants-141500157.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>